Maria J. Redondo Lab

Understanding diabetes heterogeneity to advance precision prevention, diagnosis and treatment.

About the Lab

The Redondo Lab at Baylor College of Medicine and Texas Children's Hospital investigates why individuals differ in their susceptibility to diabetes, clinical presentation, disease progression and response to treatment.

Our research is guided by the concept that multiple diabetogenic mechanisms—including autoimmune, genetic, and metabolic processes—may coexist within an individual. These processes can contribute to disease in different ways and may not be fully captured by conventional distinctions between type 1 and type 2 diabetes.

We propose that a more complete understanding of the mechanisms contributing to diabetes in each person, rather than reliance exclusively on diagnostic categories, may improve prediction of disease progression and guide more individualized prevention and treatment strategies.

Led by Maria J. Redondo, M.D., Ph.D., MPH, Professor of Pediatrics at Baylor College of Medicine, our lab integrates clinical epidemiology, genetics, longitudinal cohort studies and translational research through multidisciplinary national and international collaborations.

Our Research

Type 1 diabetes (T1D) is an autoimmune disease, but its development and progression may also be influenced by mechanisms traditionally associated with type 2 diabetes (T2D).

Our research investigates how T2D-associated factors—including obesity, insulin resistance, and genetic susceptibility—contribute to T1D heterogeneity and disease progression, both before and after clinical onset.

Our studies have identified associations between metabolic and genetic factors and differences in T1D phenotype and progression, with effects that may vary according to age, genetic susceptibility, and other individual characteristics.

Our current research, supported by Breakthrough T1D, investigates the mechanisms through which obesity may influence progression along the preclinical stages of T1D.

Understanding these relationships may identify new targets and approaches for preventing or delaying disease progression.

Genetic factors influence susceptibility to T1D, but they may also contribute to differences in disease progression and response to treatment.

Our research has extended the application of T1D genetic risk scores beyond disease susceptibility to investigate their ability to predict progression through preclinical disease stages.

Building on these findings, we are investigating genetic determinants of response to disease-modifying therapies in T1D prevention and new-onset clinical trials. This research is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH).

Our goal is to identify reproducible genetic predictors of treatment response that could eventually help guide the selection of interventions and improve individualized prevention and treatment strategies.

Diabetes is traditionally classified into distinct diagnostic categories, particularly T1D and T2D. However, autoimmune, metabolic and genetic mechanisms may coexist within an individual, contributing to different degrees to the development and clinical expression of diabetes.

These overlapping mechanisms can complicate diagnosis and may help explain differences in disease progression and response to treatment among individuals assigned the same diabetes type.

Our research investigates how overlapping diabetogenic mechanisms may inform approaches that move beyond the limitations of conventional diabetes classification.

The NIH-funded DISCOVER (Diabetes Study of Children of Diverse Ethnicity and Race) study investigates whether genetic risk scores, combined with clinical and biological characteristics, can improve diabetes classification in children from diverse racial and ethnic backgrounds.

Our overarching objective is to advance a more individualized understanding of diabetes, in which prognosis and treatment increasingly reflect the mechanisms and clinical characteristics present in each individual rather than relying exclusively on conventional diagnostic categories.

Collaborative Research

The Redondo Lab conducts multicenter research in collaboration with investigators specializing in diabetes genetics, immunology, epidemiology, metabolism, biostatistics and clinical trials.

Our collaborative research includes participation in major national and international research networks, including:

  • Type 1 Diabetes TrialNet
  • Rare and Atypical Diabetes Network (RADIANT)
  • SEARCH for Diabetes in Youth Study
  • Network for Pancreatic Organ Donors with Diabetes (nPOD)

We also collaborate with investigators at Baylor College of Medicine and Texas Children's Hospital, including the Texas Children's Hospital Data Science group, contributing to initiatives that integrate clinical expertise, large patient populations, genetics and data science to address important questions in pediatric diabetes and endocrinology.

Mentorship and Research Training

Mentoring and training future investigators are central components of the Redondo Lab.

We provide research opportunities for junior faculty, fellows, residents, medical students, graduate students, undergraduate students and high school students.

Mentees participate in clinical and translational research, including developing scientific questions, designing studies, analyzing and interpreting data, presenting findings and preparing manuscripts.

We emphasize critical thinking, scientific rigor, collaboration, and the progressive development of research independence. Our mentoring approach encourages trainees to work collaboratively, learn from more experienced investigators and take increasing ownership of their research projects.

Clinical Research Opportunities

Our lab contributes to clinical and translational research involving individuals with diabetes and those at risk of developing the disease.

For information about clinical studies and opportunities to participate in research, please visit the Baylor College of Medicine Pediatric Diabetes and Endocrinology Clinical Studies webpage.

Selected Publications

The following publications illustrate our principal contributions to understanding diabetes heterogeneity, genetic prediction and progression toward precision prevention and treatment.

  1. Redondo MJ, et al. TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes. Diabetes Care. 2018;41(2):311–317.
  2. Redondo MJ, et al. A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. Diabetes Care. 2018;41(9):1887–1894.
  3. Redondo MJ, et al. The Influence of Type 2 Diabetes-Associated Factors on Type 1 Diabetes. Diabetes Care. 2019;42(8):1357–1364.
  4. Ferrara-Cook C, et al. Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents. Diabetes Care. 2020;43(3):580–587.
  5. Redondo MJ, et al. The Clinical Consequences of Heterogeneity Within and Between Different Diabetes Types. Diabetologia. 2020;63(10):2040–2048.
  6. Redondo MJ, Morgan NG. Heterogeneity and Endotypes in Type 1 Diabetes Mellitus. Nature Reviews Endocrinology. 2023;19:542–554.
  7. You L, et al. Genetic Predictors of Response to Oral Insulin for Type 1 Diabetes Prevention. Diabetes Care. 2026;49(2):344–351.
  8. Redondo MJ, et al. BMI Normalization Is Associated With Lower Risk of Progression to Type 1 Diabetes, Primarily in Youth. Diabetes Care. 2026;49(9):1729–1737.

View a complete bibliography

Maria J. Redondo, M.D., Ph.D., MPH
Professor of Pediatrics
Baylor College of Medicine
Texas Children's Hospital
6701 Fannin Street, MWT 10th Floor
Houston, TX 77030
Email: redondo@bcm.edu